DXT treatment protects against CCH-induced hippocampal neuronal damage in the CA1 region. Its neuroprotective effect is mediated by maintaining the TOR/S6K signaling pathway. DXT treatment also decreased proinflammatory biomarkers (e.g., TNF-α, IL-1β). This evidence concerns the gene TNF and columnar cell hyperplasia of the breast.